NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Endovascular Engineering, Inc.

Endovascular Engineering, Inc.

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://endovascularengineering.com/

Last Round

Series C

Apr 7, 2026

Est. Valuation

$70M

Total Funding Raised

$137.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Endovascular Engineering, Inc. is a medical technology company that develops and deploys next-generation clot removal technologies targeting venous thromboembolism.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

thrombectomy systemendovascular devicesminimally invasive surgeryvascular interventionmedical device manufacturerinterventional cardiologyvascular surgerymechanical thrombectomyaspiration cathetermedtechclinical stage medical devicevascular disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endovascular Engineering, Inc. Comps

Public and private peers based on sector, stage, and business model.

Endovascular Engineering, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Endovascular Engineering, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 7, 2026
Series BFeb 18, 2025
Series A ExtensionApr 5, 2022
GrantSep 20, 2021

Key People

Founding team and executive leadership

Mike Rosenthal

Chief Operating Officer, Co-Founder

Founding Team

Justin Farry

CFO

Executive Team

Endovascular Engineering, Inc. Investors

Notable investors and investment history

Endovascular Engineering, Inc. investors
InvestorRounds
NIH RADxGrant
415 CapitalSeries C, Series B
Gilde HealthcareSeries C
Santé VenturesSeries C, Series B, Series A Extension
Norwest Venture PartnersSeries C
Panakès PartnersSeries C, Series B
M&L HealthcareSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2026

    $80M Series C round completed.

  • Sep 7, 2025

    Grew 23% QoQ from 30 to 37 employees.

Endovascular Engineering, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endovascular Engineering, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endovascular Engineering, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range49
Year Founded2019
Last FundingApr 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.